Citizens & Northern Corp Has $1.13 Million Holdings in Becton, Dickinson and Company $BDX

Citizens & Northern Corp grew its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 31.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,569 shares of the medical instruments supplier’s stock after buying an additional 1,581 shares during the quarter. Citizens & Northern Corp’s holdings in Becton, Dickinson and Company were worth $1,132,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the company. GQG Partners LLC bought a new stake in Becton, Dickinson and Company in the first quarter worth approximately $689,833,000. Vanguard Group Inc. increased its position in Becton, Dickinson and Company by 4.7% during the first quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier’s stock worth $6,414,322,000 after buying an additional 1,259,750 shares during the last quarter. Nuveen LLC bought a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth about $211,097,000. Kingstone Capital Partners Texas LLC bought a new position in shares of Becton, Dickinson and Company in the 2nd quarter valued at approximately $155,080,000. Finally, Massachusetts Financial Services Co. MA boosted its position in Becton, Dickinson and Company by 10.8% during the first quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier’s stock worth $1,567,654,000 after purchasing an additional 667,957 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $211.00 target price on shares of Becton, Dickinson and Company in a research note on Thursday, October 16th. Wells Fargo & Company raised their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research report on Friday, August 8th. Morgan Stanley boosted their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Three research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $205.40.

Becton, Dickinson and Company Stock Performance

Shares of NYSE BDX opened at $188.97 on Wednesday. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The business has a fifty day simple moving average of $190.46 and a 200 day simple moving average of $184.29. The firm has a market capitalization of $54.16 billion, a price-to-earnings ratio of 33.99, a PEG ratio of 1.49 and a beta of 0.25. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company had revenue of $5.32 billion during the quarter. Sell-side analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the company’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the sale, the director directly owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 1,838 shares of company stock worth $348,392 over the last quarter. 0.36% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.